Literature DB >> 20478344

Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx.

Kenji Noda1, Satoru Kodama, Shingo Umemoto, Nobuyuki Abe, Takashi Hirano, Masashi Suzuki.   

Abstract

The efficacy of alpha-galactosylceramide (alpha-GalCer) as a mucosal adjuvant was examined. Mice were immunized intranasally with nontypeable Haemophilus influenzae (NTHi) P6 protein and alpha-GalCer. P6-specific antibody responses in the form of P6-specific IgA in nasal washes and serum IgG titers were significantly elevated. Splenic CD4(+) T cells expressed P6-specific Th1 and Th2 cytokine mRNA. In addition, NTHi was quantified in nasal washes following NTHi challenges, and the clearance of NTHi from the nasopharynx was also enhanced. These results indicate that alpha-GalCer might be an effective mucosal adjuvant. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20478344     DOI： 10.1016/j.vaccine.2010.05.005

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 2.  Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.

Authors:  Timothy F Murphy
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

3.  Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Authors:  Lissette S Velasquez; Samantha Shira; Alice N Berta; Jacquelyn Kilbourne; Babu M Medi; Ian Tizard; Yawei Ni; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Vaccine       Date:  2011-06-02       Impact factor: 3.641

4.  CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Authors:  C Paget; M T Chow; N A Gherardin; P A Beavis; A P Uldrich; H Duret; M Hassane; F Souza-Fonseca-Guimaraes; D A Mogilenko; D Staumont-Sallé; N K Escalante; G R Hill; P Neeson; D S Ritchie; D Dombrowicz; T Mallevaey; F Trottein; G T Belz; D I Godfrey; M J Smyth
Journal:  Immunol Cell Biol       Date:  2014-11-11       Impact factor: 5.126

5.  Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.

Authors:  Elizabeth S DeLyria; Dapeng Zhou; Jun Soo Lee; Shailbala Singh; Wei Song; Fenge Li; Qing Sun; Hongzhou Lu; Jinhui Wu; Qian Qiao; Yiqiao Hu; Guodong Zhang; Chun Li; K Jagannadha Sastry; Haifa Shen
Journal:  Carbohydr Res       Date:  2014-12-03       Impact factor: 2.104

Review 6.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

7.  Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure.

Authors:  Matteo De Chiara; Derek Hood; Alessandro Muzzi; Derek J Pickard; Tim Perkins; Mariagrazia Pizza; Gordon Dougan; Rino Rappuoli; E Richard Moxon; Marco Soriani; Claudio Donati
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-25       Impact factor: 11.205

Review 8.  The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens.

Authors:  Mark L Lang
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561

9.  Mucosal vaccine adjuvants update.

Authors:  Joon Haeng Rhee; Shee Eun Lee; Soo Young Kim
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

10.  The role of TLR2 and bacterial lipoprotein in enhancing airway inflammation and immunity.

Authors:  Amit A Lugade; Paul N Bogner; Timothy F Murphy; Yasmin Thanavala
Journal:  Front Immunol       Date:  2011-04-27       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.